Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rocco Buccheri has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    3,4-Dihydropyrimidin-2(1H)-One Hybrids as Phenotypic Anti-Breast Cancer Agents: Synthesis, Colony-Formation Profiling and Computational Target Deconvolution

    by Hadeel D. Sultan, Rocco Buccheri, Anas J. Rasras, Mohammad S. Alzubi, Eyad A. Younes, Placido Mineo, Maria S. Molonia, Francesco Cimino, Antonio Rescifina, Nicola Micale

    3,4-Dihydropyrimidin-2(1H)-ones (DHPMs) are privileged heterocyclic scaffolds with broad biological activities. Sixteen DHPM hybrids (4a–p) carrying para- or ortho-aryloxy linkers and diverse terminal amines were prepared through a modular propargylation, Mannich-type, and Biginelli sequence. The compounds were ranked by NIH/3T3 cytotoxicity, MCF-7 antiproliferative activity (SRB assay), and colony formation under continuous exposure at the MCF-7 IC25. Compounds 4a and 4m were the most potent in MCF-7 cells (IC50 = 10.7 and 11.6 µM; preliminary selectivity indices of 9.6 and 9.1), but 4m inhibited colony formation by 68.3% compared with 25.3% for 4a, supporting its prioritization as the most balanced lead. Ligand-based target prediction followed by GNINA screening of seven candidate targets identified TOP2A as the best match to the experimental pIC50 ranking (Pearson r = 0.883, Spearman ρ = 0.893, n = 7), with Eg5/KIF11 as a secondary comparator. Docking, 200 ns molecular dynamics, and MM/PBSA estimates were compatible with this hypothesis but did not constitute experimental target validation. These data identify 4m as a starting point for DHPM-based antiproliferative agents and TOP2A as a hypothesis to be tested experimentally.

  • Open Access

    Beyond the Score: Fixed-Budget Benchmarking of Virtual Screening Integration Strategies for Decision-Centric Drug Discovery

    by Elisabetta Grazia Tomarchio, Rocco Buccheri, Antonio Rescifina

    Virtual screening (VS) workflows often combine structure- and ligand-based methods; however, their value depends on the number of compounds that can be tested. We benchmarked 20 fixed-budget strategies derived from molecular docking (GNINA CNN score), maximum common substructure (MCS) similarity, and a calibrated machine-learning (ML)-QSAR classifier across five pharmacologically diverse targets. Individual methods, best-rank and worst-rank fusion, mean-rank consensus, and sequential funnels were evaluated at 1%, 5%, and 10% library fractions, with every strategy selecting the same number of compounds. ML-QSAR was the strongest standalone method, recovering 47.6%, 81.6%, and 84.4% of actives at the three cutoffs. At the 1% budget, ML-QSAR achieved the highest mean hit recovery (47.6% recall; 99.2% precision). At 5% and 10%, best-rank fusion of QSAR and MCS produced the highest mean recall (83.2% and 86.4%). Among the sequential workflows, QSAR → MCS achieved the highest 1% hit recovery (45.2 ± 3.3% recall), whereas docking-first funnels consistently underperformed under the default, non-optimized conditions evaluated in this study. Target-level results showed substantial variability in MCS-containing workflows and limited benefits from adding docking without target-specific optimization. Under matched assay budgets, a validated ligand-based predictor or a simple two-method rank-fusion scheme provided the highest observed mean hit recovery without requiring elaborate integration.


  • Open Access

    An Integrated in Silico and SPR-based Workflow Identifies FDA-Approved Drugs as Previously Unrecognized SIRT3 Binders

    by Rocco Buccheri, Alessia Distefano, Chiara Zagni, Giuseppe Grasso, Anna Piperno, Antonio Rescifina

    Ataxia–Telangiectasia (AT) is a rare disorder characterized by ATM deficiency and mitochondrial dysfunction. Because SIRT3 contributes to mitochondrial homeostasis in ATM-deficient settings, it represents a relevant molecular context for repurposing-oriented target-engagement studies. Here, we present an integrated computational and biophysical workflow designed to identify experimentally tractable SIRT3 binders within a clinically approved chemical space. A curated dataset of 2,342 FDA-approved drugs was screened using hierarchical GNINA-based virtual screening, SAveRUNNER network analysis, triplicate 300 ns molecular dynamics simulations, post-MD redocking, MM/PBSA calculations, and experimental SPR validation. Four compounds were prioritized for further investigation: binimetinib, olaparib, mizolastine, and teniposide. Surface plasmon resonance (SPR) demonstrated direct binding of all four compounds to recombinant SIRT3, with equilibrium dissociation constants in the nano- to submicromolar range. Binimetinib showed the highest apparent affinity (KD = 21.28 ±7 nM), followed by olaparib (84 ±8.1 nM), mizolastine (138 ±11 nM), and teniposide (811.25 ±5.3 nM). Computational analyses supported the compatibility of these ligands with dynamically relaxed SIRT3 binding-site conformations and enabled the efficient prioritization of experimentally validated binders. These results support the value of an integrated in silico/SPR pipeline for identifying SIRT3-binding scaffolds and provide a basis for future enzymatic, isoform-selectivity, and cellular studies in ATM-deficient disease models.

  • Open Access

    Structure-Guided Repurposing of Approved Drugs Identifies Aprepitant and Mavorixafor as Putative δ-Opioid Receptor Agonist Candidates

    by Rocco Buccheri, Carlo Reale, Alessandro Coco, Carmela Parenti, Lorella Pasquinucci, Antonio Rescifina

    δ-opioid receptor (DOR) is a promising therapeutic target for developing safer treatments for pain and neuroprotection. In this study, we applied a structure-guided drug-repurposing workflow to identify FDA-approved drugs with predicted DOR-binding and agonist-like structural features. Using a validated GNINA-based docking protocol with an active-state DOR model (PDB ID: 6PT3), we screened 2342 approved compounds and identified 39 candidates with predicted submicromolar binding affinities. These hits were further evaluated through molecular dynamics simulations, binding pocket volume analysis, and principal component analysis, which enabled the prioritization of two leading candidates, aprepitant and mavorixafor. Both compounds formed stable receptor-ligand complexes, maintained persistent interactions with Asp128, promoted contraction of the orthosteric pocket, and retained favorable redocking scores on the MD-refined receptor conformations. Overall, these results identify aprepitant and mavorixafor as promising putative DOR agonists and provide a rational foundation for their experimental validation through binding, functional, and in vivo pain studies in the future.


  • Open Access

    Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment

    by Massimiliano Cordaro, Giulia Neri, Shoeb Anwar Mohammed Khawja Ansari, Rocco Buccheri, Angela Scala, Anna Piperno

    This review provides a comprehensive overview of the therapeutic potential of omaveloxone (OMA) for the treatment of Friedreich’s ataxia (FA), along with an analysis of the historical development and current status of the synthetic strategies for OMA production. OMA activates the nuclear factor-2-(erythroid-2)-related (Nrf2) pathway in vitro and in vivo, in both animal models and humans. The Nrf2 pathway plays a crucial role in the cellular response to oxidative stress. Furthermore, OMA has been shown to mitigate mitochondrial dysfunction, restore redox homeostasis and downregulate nuclear factor-κB (NF-κB), a key mediator of inflammatory responses. Through these mechanisms, OMA contributes to tissue protection and inflammation reduction in patients with FA. The review also highlights future perspective, focusing on the challenges associated with OMA reprofiling through innovative drug delivery approaches and its potential repurposing for diseases beyond FA.


  • Open Access

    High-Throughput, High-Quality: Benchmarking GNINA and AutoDock Vina for Precision Virtual Screening Workflow

    by Rocco Buccheri, Antonio Rescifina

    Drug discovery is an intricate and resource-intensive process in which computational approaches, such as molecular docking, are essential, particularly in the early stages, to identify potential hits. However, docking still has many drawbacks, including problems in managing protein flexibility and the reliability of scoring functions. In this paper, we systematically compared the performance of AutoDock Vina, one of the most widely used open-source docking tools, with GNINA. This advanced evolution integrates convolutional neural networks (CNNs) for pose scoring. The comparison was conducted on ten heterogeneous protein targets, including metalloenzymes, kinases, and G-protein-coupled receptors (GPCRs). With the ability to accurately replicate binding poses and their energy values, GNINA showed outstanding performance in both virtual screening (VS) of active ligands and re-docking steps of co-crystallized ligands. GNINA’s enhanced ability to accurately distinguish between true positives and false positives—a specificity not found with AutoDock Vina—is confirmed by ROC curves and Enrichment Factor (EF) results. Therefore, we propose an integrated GNINA-based workflow that can significantly enhance the quality and reliability of docking results, providing a valuable tool for optimizing the initial stages of drug discovery.


  • Open Access

    High-Throughput, High-Quality: Unlocking GNINA for Precision Virtual Screening

    by Rocco Buccheri, Antonio Rescifina

    Drug discovery is an intricate and resource-intensive process in which computational approaches such as molecular docking are essential, particularly in the early stages, to identify possible hits. However, docking still has many drawbacks, including problems in managing protein flexibility and the reliability of scoring functions. In this paper, we systematically compared the performance of AutoDock Vina, one of the most widely used open-source docking tools, with GNINA. This advanced evolution integrates convolutional neural networks (CNNs) for pose scoring. The comparison was conducted on ten heterogeneous protein targets, including metalloenzymes, kinases, and G-protein-coupled receptors (GPCRs). With the ability to accurately replicate binding poses and their energy values, GNINA showed outstanding performance in both virtual screening (VS) of active ligands and re-docking steps of co-crystallized ligands. GNINA's enhanced ability to accurately distinguish between true positives and false positives – a specificity not found with AutoDock Vina – is confirmed by ROC curves and Enrichment Factor (EF) results. Therefore, we propose an integrated GNINA-based workflow that can significantly enhance the quality and reliability of docking results, providing a valuable tool for optimizing the initial stages of drug discovery.

  • Open Access

    Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies

    by Rocco Buccheri, Alessandro Coco, Lorella Pasquinucci, Emanuele Amata, Agostino Marrazzo, Antonio Rescifina

    Precise binding free-energy predictions for ligands targeting metalloproteins, especially zinc-containing histone deacetylase (HDAC) enzymes, require specialized computational approaches due to the unique interactions at metal-binding sites. This study evaluates a docking algorithm optimized for zinc coordination to determine whether it could accurately differentiate between protonated and deprotonated states of hydroxamic acid ligands, a key functional group in HDAC inhibitors (HDACi). By systematically analyzing both protonation states, we sought to identify which state produces docking poses and binding energy estimates most closely aligned with experimental values. The docking algorithm was applied across HDAC 2, 4, and 8, comparing protonated and deprotonated ligand correlations to experimental data. The results demonstrate that the deprotonated state consistently yielded stronger correlations with experimental data, with R2 values for deprotonated ligands outperforming protonated counterparts in all HDAC targets (average R2 = 0.80 compared to the protonated form where R2 = 0.67). These findings emphasize the significance of proper ligand protonation in molecular docking studies of zinc-binding enzymes, particularly HDACs, and suggest that deprotonation enhances predictive accuracy. The study’s methodology provides a robust foundation for improved virtual screening protocols to evaluate large ligand libraries efficiently. This approach supports the streamlined discovery of high-affinity, zinc-binding HDACi, advancing therapeutic exploration of metalloprotein targets. A comprehensive, step-by-step tutorial is provided to facilitate a thorough understanding of the methodology and enable reproducibility of the results.


  • Open Access

    Enhancing HDAC Inhibitors Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies

    by Rocco Buccheri, Alessandro Coco, Lorella Pasquinucci, Emanuele Amata, Agostino Marrazzo, Antonio Rescifina

    Precise binding free energy predictions for ligands targeting metalloproteins, especially zinc-containing histone deacetylase (HDAC) enzymes, require specialized computational approaches due to the unique interactions at metal-binding sites. This study evaluated a docking algorithm optimized for zinc coordination to determine whether it could accurately differentiate between protonated and deprotonated states of hydroxamic acid ligands, a key functional group in HDAC inhibitors. By systematically analyzing both protonation states, we sought to identify which state produced docking poses and binding energy estimates most closely aligned with experimental values. The docking algorithm was applied across HDAC 2, 4, and 8, comparing protonated and deprotonated ligand correlations to experimental data. Results demonstrated that the deprotonated state consistently yielded stronger correlations with experimental data, with R² values for deprotonated ligands outperforming protonated counterparts in all HDAC targets (average R2 = 0.80 compared to the protonated form where R2 = 0.67). These findings emphasize the significance of proper ligand protonation in molecular docking studies of zinc-binding enzymes, particularly HDACs, and suggest that deprotonation enhances predictive accuracy. The study’s methodology provides a robust foundation for improved virtual screening protocols to evaluate large ligand libraries efficiently. This approach supports the streamlined discovery of high-affinity, zinc-binding HDAC inhibitors, advancing therapeutic exploration of metalloprotein targets. A comprehensive, step-by-step tutorial has been provided to facilitate a thorough understanding of the methodology and enable reproducibility of the results.